PMN outlook for 2021As per their PR. Let's not forget the incredible amount of Potential. PMN is extremely undervalued and will one day sky rocket! BUY AND HOLD!
Outlook
Following on from the completion of a US$7M (CDN$8.75M) financing in March 2021, we plan to advance progress toward our priority programs:
-
Advance the PMN310 monoclonal antibody, our potential “best in class” next generation Alzheimer’s treatment, into clinical testing;
-
Enhance our partnering prospects by allowing us to invest in additional validation data for key R&D programs;
-
Expand our portfolio of products and intellectual property into new target areas, using our proprietary discovery platform;
-
Advance our diagnostic programs in partnership with BCNI;
-
Achieve NASDAQ listing;
-
Expand our Board of Directors and our management team, to support a growing and ambitious scope of activity.